Skip to main content

Advertisement

Volume 3 Supplement 1

ESICM LIVES 2015

Microbiological study of ventilator-associated pneumonia (VAP) after implantation of pneumonia program zero (NZ)

Article metrics

  • 385 Accesses

Introduction

The National Survey of Nosocomial Infection Surveillance (ENVIN) is a computerized record of the incidence of nosocomial infection in ICU in Spain. In our hospital, we have drafted rules for the maintenance of the airway in mechanically ventilated patients following general recommendations.

Objectives

Describe the clinical diagnosis and microbiology of VAP after the implementation of the NZ program.

Methods

18 ICU beds. Data from ENVIN 01.04.11 / 01.04.15 (clinical diagnosis, microorganisms isolated and antibiotic resistance, inflammatory response ).

NZ: Educational campaign (presencial and by means of internet) to professionals of our unit and anesthesia-resuscitation unit (112 professionals). Were instituted mandatory measures for the prevention of VAP.

Results

01.04.11/01.04.12- 15 VAP.

- Clinical diagnosis:

support clinical radiological+new infiltrate 80%.

Extension of previous infiltrate + clinical worsening (2nd pneumonia)20%

- Germ:

A. baumanii 44.44%: resistance: amikacin, ampicilin, imipenem, tobramicin

P. aeuroginosa 22.22%: resistance: amikacin, ceftacidim, ciprofloxacin,

colistin, imipenem, levofloxacin, meropenem, piperacilina-tazobactam (P-T)

MRSA 16.67%

Polymicrobial 26.67%.

- Inflammatory response: sepsis 33.33%, severe sepsis 33.33%.

01.04.12/01.04.13-6 VAP

- Diagn:

support clinical radiological+new infiltrate 66.67%

extension of previous infiltrate + clinical worsening (2nd pneumonia) 16.67%,

CT 16.67%.

- Germ:

S. Aureus 22 .22%: no resistance

S. Maltophilla 22.22% no resistance

Polymicrobial 50%.

Without diagnostic 16.67%

- Inflammatory response: sepsis 50%, severe sepsis 33.33%, shock 16.67%

01.04.13/01.04.14- 10 VAP

- Diagn:

support clinical radiological+new infiltrate 60%

extension of previous infiltrate + clinical worsening (2nd pneumonia) 30%,

CT 10%.

- Germ:

S. Aureus 25%

E. Coli 16.67%: resistance: ciprofloxacin, amox-clav.

H. Influnzae 8.33%

P. aeuroginosa 8.33%: resistance :cefepime, ceftacidime, imipenem,

meropenem, P-T

polimicrobial 20%.

- Inflammatory response: sepsis 50%, severe sepsis 30%, shock 20%.

01.04.14/01.04.15- 3VAP

- Diagn:

support clinical radiological+new infiltrate 68.57%

extension of previous infiltrate + clinical worsening (2nd pneumonia) 22.86%

CT 8.57%.

- Germ:

A. baumanii 18.6% . Resistance: amikacin

P. aeuroginosa 16.28% . Resistance: amikacin, cefepime

S. aureus 13.95%: no resistance

Polimicrobial 28.57%

- Inflammatory response: sepsis 33.33%, severe sepsis 66.67%

Conclusions

Most of the diagnoses are made by the patient's clinical and x-ray. Each year vary germs being the most frequent S. aureus and P. aeruginosa. Usually, the most common inflammatory response is sepsis. The P. aeruginosa is the germ which has more resistance.

Grant Acknowledgment

UCI S. Cecilio

References

Author information

Correspondence to R Fernández Fernández.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Inflammatory Response
  • Severe Sepsis
  • Levofloxacin
  • Nosocomial Infection
  • Amikacin